L-histidine decarboxylase and Tourette's syndrome.

Tourette's syndrome is a common developmental neuropsychiatric disorder characterized by chronic motor and vocal tics. Despite a strong genetic contribution, inheritance is complex, and risk alleles have proven difficult to identify. Here, we describe an analysis of linkage in a two-generation pedigree leading to the identification of a rare functional mutation in the HDC gene encoding L-histidine decarboxylase, the rate-limiting enzyme in histamine biosynthesis. Our findings, together with previously published data from model systems, point to a role for histaminergic neurotransmission in the mechanism and modulation of Tourette's syndrome and tics.

[1]  J. Aruga,et al.  Slitrk1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities , 2010, Molecular Psychiatry.

[2]  H. Haas,et al.  Histamine in the nervous system. , 2008, Physiological reviews.

[3]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[4]  J. Schwartz,et al.  Title Brain histamine and schizophrenia : potential therapeutic applications of H 3-receptor inverse agonists studied with BF 2 . 649 , 2007 .

[5]  J. Leckman,et al.  Tourette Syndrome: The Self Under Siege , 2006, Journal of child neurology.

[6]  J. Raber,et al.  Anxiety and cognition in female histidine decarboxylase knockout (Hdc −/−) mice , 2006, Behavioural Brain Research.

[7]  Murat Gunel,et al.  Sequence Variants in SLITRK1 Are Associated with Tourette's Syndrome , 2005, Science.

[8]  K. Browman,et al.  Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia. , 2005, Inflammation Research.

[9]  Min Zhang,et al.  Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[10]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[11]  R. Spieler,et al.  Changes in motoric, exploratory and emotional behaviours and neuronal acetylcholine content and 5‐HT turnover in histidine decarboxylase‐KO mice , 2004, The European journal of neuroscience.

[12]  Ann M. Graybiel,et al.  Pathophysiology of Tourette's syndrome: striatal pathways revisited , 2003, Brain and Development.

[13]  H. Ohtsu,et al.  New functions of histamine found in histidine decarboxylase gene knockout mice. , 2003, Biochemical and biophysical research communications.

[14]  T. Wang,et al.  The Production of 53–55-kDa Isoforms Is Not Required for Ratl-Histidine Decarboxylase Activity* , 2003, Journal of Biological Chemistry.

[15]  H. Ohtsu,et al.  Increased methamphetamine‐induced locomotor activity and behavioral sensitization in histamine‐deficient mice , 2002, Journal of neurochemistry.

[16]  Peter Herscovitch,et al.  The Functional Neuroanatomy of Tourette's Syndrome: An FDG PET Study III: Functional Coupling of Regional Cerebral Metabolic Rates , 2002, Neuropsychopharmacology.

[17]  G. Csaba,et al.  Mice lacking histidine decarboxylase exhibit abnormal mast cells , 2001, FEBS letters.

[18]  Ali G. Gharavi,et al.  Molecular Mechanisms of Human Hypertension , 2001, Cell.

[19]  P. Coffino,et al.  Dominant negative mutants of ornithine decarboxylase. , 1992, The Journal of biological chemistry.

[20]  K. Kidd,et al.  A twin study of Tourette syndrome. , 1985, Archives of general psychiatry.